De Rosa Laura, Enzo Elena, Palamenghi Michele, Sercia Laura, De Luca Michele
Holostem Terapie Avanzate, S.r.l., 41125 Modena, Italy.
Centre for Regenerative Medicine "Stefano Ferrari," University of Modena and Reggio Emilia, 41125 Modena, Italy.
Cold Spring Harb Perspect Biol. 2023 Apr 3;15(4):a041229. doi: 10.1101/cshperspect.a041229.
Epidermolysis bullosa (EB) is a devastating genetic skin disease typified by a plethora of different phenotypes and ranking from severe, early lethal, to mild localized forms. Although there is no cure for EB, recent progress in pharmacology and molecular and cellular biology is boosting the development of new advanced therapeutic strategies. Here we will focus on two main categories of such therapies: (1) those aimed at controlling inflammation and inducing reepithelialization of the wounds, and (2) those, perhaps more challenging and ambitious, that aim to permanently regenerate a fully functional epidermis, which requires targeting of epidermal stem cells. In both cases, the genetic variants underlying the different EB forms and factors, such as genetic background, modifier genes, comorbidities, and lifestyle, all of which impinge on EB genotype-phenotype correlation, need to be defined.
大疱性表皮松解症(EB)是一种严重的遗传性皮肤病,具有多种不同的表型,从严重的早期致死型到轻度的局限性形式不等。尽管目前尚无治愈EB的方法,但药理学以及分子和细胞生物学领域的最新进展正在推动新的先进治疗策略的发展。在此,我们将重点关注此类治疗的两个主要类别:(1)旨在控制炎症并诱导伤口重新上皮化的治疗方法,以及(2)那些可能更具挑战性和雄心勃勃的治疗方法,即旨在永久再生功能完全正常的表皮,这需要针对表皮干细胞。在这两种情况下,都需要明确不同EB形式背后的基因变异以及诸如遗传背景、修饰基因、合并症和生活方式等因素,所有这些因素都会影响EB的基因型-表型相关性。